Neuromyelitis optica

Print Friendly and PDF

Neuromyelitis optica (NMO) is an inflammatory disorder of the central nervous system (CNS) that predominantly affects the optic nerves and spinal cord.

Although it has been initially considered to be a severe variant of multiple sclerosis (MS), the finding that most NMO patients have autoantibodies against aquaporin-4 (AQP4) has improved our knowledge of its pathogenesis and led to the concept that NMO is a disease distinct from MS. The antibody is pathogenic and its seropositivity allows for early and accurate diagnosis even in the absence of cardinal findings of optic neuritis and myelitis. NMO is now considered as an anti-AQP4 antibody-mediated astrocytopathy, and different from a demyelinating disorder as is MS.

Diagnostic criteria

The identification of this specific biomarker was a breakthrough in NMO research and prompted a revision of the NMO diagnostic criteria in 2006 (Wingerchuk et al., 2006). The specificity of AQP4-IgG facilitated observations that the clinical and neuroimaging spectrum of NMO was even broader than previously recognized. In 2007, the term NMO spectrum disorders (NMOSD) (Wingerchuk et al., 2007) was introduced to include AQP4-IgG seropositive patients with single or recurrent events of longitudinally extensive myelitis and recurrent or simultaneous bilateral optic neuritis. It also included patients with concomitant systemic autoimmunity, such as systemic lupus erythematosus or Sjögren syndrome.

It is important to note that brain lesions in NMO and NMOSD are not uncommon, do not rule out the diagnosis, and show characteristic patterns. Although 2006 NMO diagnostic criteria required optic nerve and spinal cord involvement, more restricted or more extensive CNS involvement may occur. Recent studies have demonstrated that a significant proportion of AQP4 antibody–positive patients did not meet 2006 NMO/NMOSD criteria (Sato et al., 2013), including: short-segment transverse myelitis, monophasic unilateral optic neuritis with severe visual impairment, and brainstem syndromes with persisting hiccups, nausea or vomiting episodes. Accordingly, an International Panel for NMO Diagnosis (IPND) has been working to develop revised diagnostic criteria using systematic literature reviews.

A new possible diagnostic marker

Approximately 90% of adult patients with NMO are positive for autoantibodies against AQP4. Therefore, a proportion of patients with a clinical NMO or NMOSD phenotype remains AQP4 antibody-seronegative, despite the use of the best assays available on serum samples collected during an acute attack before any treatment.

Recently, autoantibodies against myelin oligodendrocyte glycoprotein (MOG) were reported in patients who were clinically diagnosed with NMOSD and negative for AQP4 antibodies. Compared with patients with AQP4 antibodies, adult individuals with MOG antibodies were more frequently male, had a more restricted phenotype, more frequently had bilateral simultaneous optic neuritis, more often had a single attack, had lesions involving the lower portion of the spinal cord, and usually demonstrated better recovery after an attack. MOG-autoantibodies are relatively more common in pediatric inflammatory and demyelinating syndromes compared to adults, especially in children with ADEM, MS, and the NMOSD phenotype. (Sato et al., 2014; Weinshenker & Wingerchuk, 2014; Miyauchi et al., 2014; Kitley et al., 2014; Rostasy et al., 2013)

Cognitive impairment and cortical degeneration in neuromyelitis optica

Although the brain is widely recognized to be relatively spared in NMOSD, most studies using advanced neuroimaging techniques have found abnormalities in normal-appearing gray matter (NAGM) as well as normal findings or minimal changes in normal-appearing white matter. These findings suggest selective or more severe damage of gray matter, which is a site of high AQP4 expression. Cognitive impairment in patients with NMOSD has been recently reported even in the limited forms of the disease. Published data also describe the pathological processes consisting of inflammatory events with a pattern-specific loss of AQP4 immunoreactivity, cortical neurodegeneration, with no evidence of cortical demyelination (Saji et al., 2013; Lucchinetti et al., 2014).


Treatment of NMO/NMOSD includes both the management of acute attacks and the prevention of future exacerbations. The goal of acute therapy is to minimize irreversible damage and accelerate recovery. Plasmapheresis following IV methyl-prednisolone effectively removed anti-AQP4 anti¬bodies and was accompanied by a substantial improvement in the neurological disability of patients with NMOSD according to recently published studies. (Kimbrough et al., 2012; Kim et al., 2013; Tenembaum et al., 2013; Kowarik et al., 2014; Morgan et al., 2014)

Preventative therapy should lower the frequency and severity of future relapses, and has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO relapses: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate, and mitoxantrone.

In general it is recommended to start with one of the following four first-line options: azathioprine, mycophenolate mofetil, rituximab, or prednisone. Cost, availability, patient choice, route of administration, side effects, and the prescribing physician's familiarity with the specific agent will also influence the treatment decision. 

Further reading

Kim, S. H., Kim, W., Huh, S. Y., Lee, K. Y., Jung, I. J., & Kim, H. J. (2013). Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. Journal of Clinical Neurology (Korea), 9(1), 36–42. doi:10.3988/jcn.2013.9.1.36

Kimbrough, D. J., Fujihara, K., Jacob, A., Lana-Peixoto, M. A., Isabel Leite, M., Levy, M., ... Wingerchuk, D. M. (2012). Treatment of neuromyelitis optica: Review and recommendations. Multiple Sclerosis and Related Disorders. doi:10.1016/j.msard.2012.06.002

Kitley, J., Waters, P., Woodhall, M., Leite, M. I., Murchison, A., George, J., ... Palace, J. (2014). Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurology, 71(3), 276–83. doi:10.1001/jamaneurol.2013.5857

Kowarik, M. C., Soltys, J., & Bennett, J. L. (2014). The treatment of neuromyelitis optica. Journal of Neuro-Ophthalmology : The Official Journal of the North American Neuro-Ophthalmology Society, 34(1), 70–82. doi:10.1097/WNO.0000000000000102

Lucchinetti, C. F., Guo, Y., Popescu, B. F. G., Fujihara, K., Itoyama, Y., & Misu, T. (2014). The pathology of an autoimmune astrocytopathy: Lessons learned from neuromyelitis optica. In Brain Pathology (Vol. 24, pp. 83–97). doi:10.1111/bpa.12099

Miyauchi, A., Monden, Y., Watanabe, M., Sugie, H., Morita, M., Kezuka, T., ... Yamagata, T. (2014). Persistent presence of the anti-myelin oligodendrocyte glycoprotein autoantibody in a pediatric case of acute disseminated encephalomyelitis followed by optic neuritis. Neuropediatrics, 45(3), 196–9. doi:10.1055/s-0034-1371179

Morgan, S. M., Zantek, N. D., & Carpenter, A. F. (2014). Therapeutic plasma exchange in neuromyelitis optica: a case series. Journal of Clinical Apheresis, 29(3), 171–177. doi:10.1002/jca.21304

Rostásy, K., Mader, S., Hennes, E. M., Schanda, K., Gredler, V., Guenther, A., ... Reindl, M. (2013). Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Multiple Sclerosis (Houndmills, Basingstoke, England), 19(8), 1052–9. doi:10.1177/1352458512470310

Saji, E., Arakawa, M., Yanagawa, K., Toyoshima, Y., Yokoseki, A., Okamoto, K., ... Kawachi, I. (2013). Cognitive impairment and cortical degeneration in neuromyelitis optica. Annals of Neurology, 73(1), 65–76. doi:10.1002/ana.23721

Sato, D. K., Callegaro, D., Lana-Peixoto, M. A., Waters, P. J., De Haidar Jorge, F. M., Takahashi, T., ... Fujihara, K. (2014). Distinction between MOG antibodypositive and AQP4 antibody-positive NMO spectrum disorders. Neurology, 82(6), 474–481. doi:10.1212/WNL.0000000000000101

Sato, D. K., Nakashima, I., Takahashi, T., Misu, T., Waters, P., Kuroda, H., ... Aoki, M. (2013). Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology, 80(24), 2210–2216. doi:10.1212/WNL.0b013e318296ea08

Tenembaum, S. N. (2013). Treatment of multiple sclerosis and neuromyelitis optica in children and adolescents. Clinical Neurology and Neurosurgery, 115(SUPPL.1). doi:10.1016/j.clineuro.2013.09.016

Weinshenker, B. G., & Wingerchuk, D. M. (2014). The two faces of neuromyelitis optica. Neurology, 82(6), 466–467. doi:10.1212/WNL.0000000000000114

Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007). The spectrum of neuromyelitis optica. Lancet Neurology. doi:10.1016/S1474-4422(07)70216-8

Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006). Revised diagnostic criteria for neuromyelitis optica. Neurology, 66(10), 1485–1489. doi:10.1212/01.wnl.0000216139.44259.74
APA Style
Neuromyelitis optica. (n.d.). In ICNApedia. Retrieved November 20,2019 11:49:08 from
MLA Style
"Neuromyelitis optica." ICNApedia: The Child Neurology Knowledge Environment, Inc. May 06, 2018. Web. November 20,2019 11:49:08
AMA Style
ICNApedia contributors. Neuromyelitis optica. ICNApedia, The Child Neurology Knowledge Environment. May 06, 2018. Available at: November 20,2019 11:49:08.

User reviews

No readers have reviewed this article yet
Already have an account?
Has this page got sufficient citations and have they come from trustworthy sources
Does this article cover the topic area adequately
Well written
Is the article well organized and well written
You will be able to upload media right after you submit your review.